

FNP-223 | Mechanism of Action



FNP-223 is a novel **OGA inhibitor** positioned as a potential **disease-modifying treatment for PSP**¹

OGA inhibition as disease-modifying treatment



Under normal conditions there is an antagonistic cross-talk between glycosylation and phosphorylation

Glycosylation acts as a **protective layer preventing tau from being phosphorylated**². OGA enzyme removes glycosylated residues, increasing probability of phosphorylation.

FNP-223 is a novel OGA inhibitor: by inhibiting OGA, it maintains more residues glycosylated **avoiding tau phosphorylation**.

In pathological conditions there is an imbalance that **favors Tau phosphorylation**. Phosphorylation destabilises Tau and causes it to **disaggregate from microtubules**³: increasing neuronal instability and **self-aggregating into toxic neurofibrillary tangles**